NeoGenomics Inc (NEO) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Total Revenue Chart for NeoGenomics Inc
NeoGenomics Inc (NEO) revenue for FY2025 was USD 727.3M, a 10.1% change from FY2024. NeoGenomics Inc's revenue grew from USD 252.4K in 2000 to USD 727.3M in 2025 (288063.0% over 25 years). Earnings per share moved from USD -0.14 in 2011 to USD -5.81 in 2022. Revenue compound annual growth rate: 5-year CAGR of 10.4%, 10-year CAGR of 22.0%, 20-year CAGR of 34.7%.
Total Revenue (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $2.14B
- Implied Share Price
- $16.65
- Enterprise Value
- $2.66B
- Revenue (TTM)
- $766.29M
- EBITDA
- $24.32M
- Profit Margin
- -6.77%
- Trailing P/E
- —
- Forward P/E
- 222.22
- Price/Book (MRQ)
- 3.00
- Price/Sales (TTM)
- 2.83
- EV/EBITDA
- 197.32
- EV/Revenue
- 3.47
- Dividend Yield
- —
- Book Value
- $6.14
- Free Cash Flow (FY2025)
- -$21.78M
- Free Cash Flow Yield
- -1.02%
Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.